London, UK (PRWEB UK) 11 September 2013
A new partnership between InferMed and Egton Medical Information Systems (EMIS) sees InferMed’s Arezzo Pathways integrated with EMIS Web. This integration assists clinical practice by supporting compliance with care pathways to enable better patient outcomes.
InferMed’s Arezzo Pathways is a web-based solution that takes the latest clinical evidence, matches it with an individual patient and provides a recommended care pathway specifically for that patient. Arezzo Pathways generates decision options, takes into account predictive risk factors and enables complete care pathway management that can result in reduced unplanned admissions, elimination of variance and clinically appropriate referrals.
EMIS Web helps GPs to diagnose, treat and monitor patients, and to spot future health issues before they become a problem. Integrating the power of Arezzo Pathways with EMIS Web supports GPs in making evidence-based decisions tailored to individual patients.
Shaun O’Hanlon, Clinical Development Director for EMIS, said: “We welcome InferMed’s Arezzo software as part of the EMIS partner programme, and believe it will assist EMIS Web users in managing long-term conditions for their patients. As with all of our partners, InferMed has committed to our requirement for interoperability and shared standards - enabling our products to work together seamlessly for the ultimate benefit of all.”
Commenting on the significance of InferMed’s new partnership with EMIS Duane Lawrence, CEO of InferMed Limited, added: “We recognise the leading and trusted position EMIS has with clinicians across the UK and are delighted that our partnership sees InferMed’s Arezzo technology integrated into their clinical management system. Put alongside the Arezzo-based NHS Direct digital solutions in England, Arezzo Pathways integrated with EMIS Web will provide opportunities for coordinating and improving care while reducing unnecessary costs.”
InferMed’s partnership with EMIS in the UK is similar to a New Zealand-wide BPAC (Best Practice Advocacy Centre) agreement, where InferMed’s Arezzo clinical decision support technology has been integrated with the patient records. Similarly to what will now happen in the UK with EMIS, the use of Arezzo in New Zealand has included taking existing paper-based guidelines, transforming them with Arezzo into ‘active’ guidelines at the point of care and implementing them across 90% of GPs in the country. With active decision support as part of their standard workflow the GPs using Arezzo-based guidelines in New Zealand have reduced childhood admissions to hospital for Asthma by over 50% and so have made a tangible difference in improving care while reducing unnecessary costs.
EMIS Group plc is the UK's leading supplier of software and related services to GP practices and a major supplier to high street pharmacies. As at 30 June 2013, there were 2,580 live EMIS Web practices.
Since 1999, InferMed has provided software and services to support best practice in medicine. Through its MACRO EDC application and Arezzo® decision support technology, patients receive safe, up-to-date medical treatment based on best available clinical evidence. InferMed solutions tame the volume and complexity of clinical information, transforming it into actionable knowledge, available at the point of care for clinicians in research and practice, and to patients in their homes. InferMed solutions are accessed over a million times per month across Europe, North America and Australasia.
In April 2012 InferMed won a prestigious Queen’s Award for Enterprise in Innovation for its work in developing and commercialising decision support systems for healthcare using its Arezzo Clinical Decision Support technology. The Queen’s Award acknowledged the growing vital role played by Arezzo in encouraging the consistent use and development of good practice, helping to raise standards of clinical care and ensuring that medicine is right first time, every time.
If you would like more information on this release, please contact InferMed Ltd on 020 7291 7410 or mark.snell(at)infermed(dot)com.